Streetwise Reports - Exclusive Articles
Investment coverage from Streetwise Reports.
Falcon Gold Corp. (FG:TSX.V; FGLDF:OTCQB) announced channel sample results confirming high-grade gold mineralization on the past-producing Master Vein of its Spitfire-Sunny Boy ("S-SB") project near Merritt, B.C. The samples come from a blasted trench along strike with the best sample averaging 59.8 g/t gold (1.74 oz./ton) over 2.2m, including 1.0m of 122 g/t gold (3.56 oz./ton). This is BIG news, in the middle of an epic bull market in precious metals.
Strong confirmation of high-grade gold at Spitfire-Sunny Boy
A second channel sample of the Master Vein, 125m southeast along strike, returned 11.4 g/t gold over 1.0m. In addition, a new potential vein structure, the Cliff Vein, was discovered down slope from the Master Vein. A grab sample of the Cliff Vein assayed up to 22.8 g/t gold.
Importantly, the geological team sampled outcrops across the entire property. These samples are undergoing whole rock geochemical analyses to provide further insights into the deposit's scale and potential for more gold occurrences.
CEO Karim Rayani commented,
"The Merritt area has a long history of exploration & gold discoveries. Explorers focused on narrow high-grade veins while not seeing the less obvious geological indications of broader mining widths. The Company's field crew has dedicated their work this season to studying the structure & geochemistry. The project continues to impress us as results come in. We believe the Nicola Lake area hosts the makings of a significant new gold camp."
The first discoveries at S-SB were in 1908. Early exploration focused on quartz veins hosting gold, copper and silver. High-grade values have been reported, including 124 to 127 g/t gold, plus 309 to 514 g/t silver. These ultra-high-grade veins have...
A Solar Tutorial: Strong Growth in the USA Over the Past Decade
According to the Solar Energy Industry Association, Wood Mackenzie Power & Renewables and the Solar Foundation, solar energy in the USA has experienced an average annual growth rate of 49% per year over the past decade. What aided this growth were U.S. federal policies such as the solar investment tax credit, rapidly declining costs (installation costs have dropped >70% over the last decade) and increasing demand across the private and public sector for clean electricity.
Despite falling hardware costs, additional room for cost improvements exists in the residential and small commercial segments. Specifically, labor, permitting, inspection, interconnection, supply chain and customer acquisition costs could further decline according to industry observers. The U.S. Energy Information Administration's (EIA, a U.S. federal agency that deals with energy-related information to support policy making), forecasts solar to be the dominant USA renewable energy source by 2050.
Solar now makes up a large share of new U.S. power capacity installations. According to the SEIA, the national trade association for the U.S. solar industry, solar has ranked first or second in new electric capacity additions in each of the last seven years through 2019. For example, during 2019, 40% of all new electric capacity added to the U.S. grid came from solar (a historical high point). Solar now contributes over 2.5% of total U.S. electrical generation versus 0.1% in 2010.
U.S. solar is no longer confined to a few key U.S. states, even though state legislation can help with adoption. While historically California dominated the U.S. solar market, other states, such as Florida and Texas have witnessed rapid growth in the past decade. That said, state level pol...
This story is the stuff of myth. It will be retold, inflated, and gilded…especially if there's a discovery.
It's a story about gold, a historical mining district, seizing opportunity and psychedelic mushrooms.
I heard about it from a good friend. It was so far-fetched, I reached out to Warwick Smith, CEO of American Pacific Mining Corp. (USGD:CSE; USGDF:OTC), a tiny, C$16 million Canadian junior, to get the truth.
You see, Warwick's company bought the Madison Project for just 20 million of its shares—worth roughly C$7.6 million today.
And the Madison Project is special.
With the acquisition, came a built in partner. Rio Tinto has a joint venture agreement on the project. It will spend $30 million to acquire 70% of the project. American Pacific gets a "carried interest." That means it doesn't have to pay another cent and it still owns 30% of whatever Rio Tinto finds.
And the potential at Madison is enormous.
This is a past producing mine in a historical mining district in Montana. Between 2005 and 2011, the mine produced 7,570 ounces of gold and 3 million pounds of copper from rocks that averaged half an ounce of gold and 25% copper per ton.
That's outrageous grade. And it justifies Rio Tinto's interest. But that isn't all. Madison is in the Butte Mining District in western Montana. It sits at the southern point of a triangle formed from the giant Anaconda mine and Barrick's Golden Sunlight mine.
This is a region steeped in mining history. The rocks here have a rich mineral endowment. Historical drilling results at Madison included 30 meters of rock that ran 24.5 grams per ton gold and another that hit 11 meters of core with 41.7 grams per ton gold.
That's the kind of grade and length that make me sit up and take notice. These aren't narrow little shoots of high grade. If Rio...
Source: Streetwise Reports 08/06/2020Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen.
Biopharmaceutical company Denali Therapeutics Inc. (DNLI:NASDAQ), which is focused on developing a broad portfolio of product candidates for treatment of neurodegenerative diseases, today announced that "DNL151 has been selected to progress into late stage studies in Parkinson's disease patients with a kinase activating mutation in LRRK2 and in sporadic Parkinson's disease patients."
The company's Chief Medical Officer Carole Ho, M.D., commented, "Safety and biomarker data from studies of our two LRRK2 molecules in Parkinson's patients support moving DNL151 into late stage clinical studies with the aim of addressing the devastating clinical decline and pathology of disease in Parkinson's patients...Our collaboration partner Biogen is a respected leader in neurodegenerative diseases and brings deep scientific and development expertise in Parkinson's disease which will allow us to accelerate our development plan and we believe increase the likelihood of ultimate success."
The firm explained that "LRRK2 is a regulator of lysosomal function, which is impaired in Parkinson's disease and may be restored by LRRK2 inhibition." The company noted that mutations in the LRRK2 gene can cause Parkinson's disease and are a leading driver of lysosomal dysfunction which often exacerbates neurodegeneration.
The company advised that it is working with its partner Biogen Inc. (BIIB:NASDAQ) in order to finalize clinical development plans for the LRRK2 program. The plans entail the commencement of two separate Parkinson's disease studies starting in 2021. The first study will be for use in patients with a kinase activating mutation in LRRK2 and the second trial in other patients with sporadic disease.
The firm stated that its two ...
Source: Streetwise Reports 08/05/2020These two CytoSorbents events are discussed in a Dawson James report.
In a July 31 research note, Dawson James analyst Jason Kolbert reported that CytoSorbents Corp. (CTSO:NASDAQ) landed a $4.4 million contract and completed a $50 million cash raise.
Kolbert discussed both. As for the cash influx, the New Jersey-based company raised about $50 million in cash at $9.50 per share for 5.2 million shares. The analyst described the raise as "well timed" and "accretive" in that CytoSorbents can use the funds to "drive the pipeline and current revenues."
As for the new contract, relayed Kolbert, it is a $4.4 million agreement with the U.S. Department of Defense for CytoSorbents' blood and plasma protection product, HemoDefend, which is now being evaluated.
Kolbert explained that HemoDefend can be employed in two ways. One is during transfusion as a filter in the line between the patient and the blood bag. The other is during storage, via biocompatible "beads" kept in the blood bag.
HemoDefend keeps donated blood fresh and thus, extends its shelf life. Also, the product removes from the blood any contaminants that were present when the blood was obtained and/or that resulted from changes to the red blood cells while in storage. "This is to minimize the current 1–5% risk chance patients have of developing a transfusion reaction," noted Kolbert.
Dawson James has a Buy rating and a $15 per share price target on CytoSorbents, the stock of which is currently trading at about $9.89 per share.Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: Non...
Viewing page 1 of 3|Next Page